Alpelisib for Insulin Resistance

This trial seeks a simpler method to measure insulin production in individuals with insulin resistance by using alpelisib, a medication for certain insulin resistance-related conditions. Participants will undergo two tests: a "hyperglycemic clamp," involving a sugar infusion to assess insulin production, and a "Mixed Meal Tolerance Test," which uses a nutritional drink to evaluate insulin response. The study welcomes individuals with a body mass index (BMI) between 18 and 45 who do not have diabetes and maintain a stable weight. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants an opportunity to contribute to groundbreaking research.

Research shows that alpelisib can cause some serious side effects. Many patients taking alpelisib experience high blood sugar levels, known as hyperglycemia, which is a common issue with the drug. In some cases, high blood sugar becomes severe, and reports indicate that patients have developed diabetic ketoacidosis, a condition where the body breaks down fat too quickly.

Most treatments for insulin resistance focus on improving insulin sensitivity through medications like Metformin, lifestyle changes, or other oral antidiabetic drugs. But Alpelisib works differently, as it targets the PI3K pathway, which is involved in cell growth and metabolism. This unique mechanism may offer a new approach to managing insulin resistance, potentially addressing root causes in a way existing treatments do not. Researchers are excited about Alpelisib because it could provide more effective control over insulin levels, especially for those who do not respond well to standard therapies.

This trial will evaluate the effects of alpelisib on insulin resistance in different groups, including those with varying body mass indices. Studies have shown that alpelisib can raise blood sugar levels and reduce the body's responsiveness to insulin, making blood sugar management more difficult. Research indicates that over 60% of people taking alpelisib experience high blood sugar. Although this trial tests alpelisib's effects on insulin resistance, it has been linked to blood sugar control issues. However, in other conditions, alpelisib reduced the risk of disease progression by 35% in people with certain genetic mutations. These findings suggest that while alpelisib has shown effectiveness in other areas, its impact on insulin resistance remains under investigation.⁶⁷⁸⁹¹⁰